Insulin glargine (LANTUS) is a new, long-acting insulin analogue with a stable pro le of action. The purpose of these studies was to evaluate the carcinogenic potential of insulin glargine in rats and mice. General toxicity studies were conducted in NMRI mice (3 months' duration) and rats (Wistar rats in the 3-and 6-month studies and Sprague-Dawley rats in the 12-month study) to determine the optimal dose of insulin glargine for long-term carcinogenicity studies. Based on these results, groups of Sprague-Dawley rats or NMRI mice (50 male, 50 female) received a daily subcutaneous dose of 2, 5, or 12.5 IU/kg of insulin glargine or 12.5 (mice) or 5 IU/kg (rats) of the reference insulin (NPH insulin) in a lifetime study. Similarly treated control and vehicle-control animals received isotonic sodium chloride (NaCl) solution or the vehicle solution, respectively. In mice, the mortality rate was comparable between all groups. In rats, the mortality rate compared with the NaCl control was signi cantly increased in the following groups: males treated with the vehicle control, all insulin glargine and NPH insulin groups, and in females in the high-dose insulin glargine and NPH insulin groups. There was no difference in the incidence of mammary tumors reported in both mice and rats when comparing the insulin glargine groups with the NaCl, vehicle-control, or the NPH insulin groups. In rats and mice, the distribution of subcutaneous malignant brous histiocytomas found at the injection site were not dose-dependent. These lesions are a rodent-speci c event and were related to chronic tissue irritation and in ammation. In rats, neuronal necrosis of the cerebrum was attributed to persistent repeated episodes of hypoglycemia induced by high doses of insulin. In these studies, there were no neoplastic ndings to indicate that insulin glargine had a systemic carcinogenic potential in mice or rats.
in healthy individuals (Ciofetta et al. 1999) . However, insulin analogs that provide a normal physiologic insulin supply have recently been developed using recombinant DNA techniques. Insulin glargine (LANTUS) is one such analog that provides a basal insulin supply with a once-daily injection (Home 2000) . Insulin glargine has two arginines added to the C terminus of the B-chain and the asparagine residue on the A-chain substituted with a glycine. The resulting insulin molecule has a pH of 6.7 and precipitates at physiologic pH in subcutaneous tissue to form a long-lasting depot with a relatively constant rate of insulin release (Rosskamp 1997) . Insulin glargine has a longer duration of action and a atter pro le of action compared with NPH insulin (Owens et al. 2000) . Studies in patients with type 1 and type 2 diabetes have shown that insulin glargine provides comparable or better glycemic control than NPH insulin, and with a reduced incidence of severe and nocturnal hypoglycemia (Pieber, Eugene-Jolchine, and Derobert 2000; Yki-Jarvinen, Dressler, and Ziemen 2000; Ratner et al. 2000; Rosenstock, Park, and Zimmerman 2000) .
Although the alteration of the amino acid sequence of insulin can confer advantageous therapeutic properties, it is also possible that these changes can alter the receptor-binding and signaling characteristics of the insulin analog. For example, previous studies have shown that the insulin analog [B10-Asp]-insulin caused mammary tumors in rats (Jorgensen, Dideriksen, and Drejer 1992) . [B10-Asp]-insulin has, however, only been tested for 2 months in patients with type 1 diabetes, but has never been used for long-term treatment (Nielsen et al. 1995) . One possible explanation for the carcinogenic activity of [B10-Asp]-insulin is that it is characterized by an increased level of binding to the insulin-like growth factor-1 (IGF-1) receptor as demonstrated by in vitro binding studies. One study in cultured rat aortic smooth muscle cells showed that [B10-Asp]-insulin had a higher af nity for the IGF-1 receptor and stimulated thymidine incorporation into DNA to a higher degree compared with insulin (maximal effect 62% § 10% higher than the maximal effect of insulin) (Bornfeldt et al. 1991) .
In vitro studies in muscle cells showed that although [B10-Asp]-insulin had a higher af nity for the IGF-1 receptor and stimulated thymidine incorporation into DNA to a greater extent compared with human insulin, insulin glargine had only a slightly higher af nity for the IGF-1 receptor and was equipotent for mitogenic activity (Bahr et al. 1997) . Analysis of insulin signaling in rat-1 broblast cells demonstrated that, with respect to insulin receptor association and dissociation kinetics, insulin receptor autophosphorylation, and thymidine incorporation, insulin glargine was equivalent to human insulin (Berti et al. 1998) .
The purpose of this study was to determine if insulin glargine has any carcinogenic potential by conducting lifetime carcinogenicity studies in rodents.
MATERIALS AND METHODS

Test Compounds
Insulin glargine (HOE901) was dissolved in an aqueous vehicle solution (glycerol 0.2 mol/l, m-cresol 0.025 mol/l, ZnCl 2 0.0002 mol/l) adjusted to pH 4.0. The vehicle group received only the vehicle solution (no ZnCl 2 ) adjusted to pH 4.0. The sham-treated control group received an isotonic sodium chloride (NaCl) solution. Human NPH insulin (HOE36H) was dissolved in a vehicle solution (glycerol 0,2 mol/l, NaH 2 PO 4 0.00135 mol/l, phenol 0.0063 mol/l, m-cresol 0.0138 mol/l, ZnCl 2 0.0001 mol/l) adjusted to pH 7.3.
Experimental Animals
Sprague-Dawley rats and Wistar rats (Charles River, Sulzfeld, Germany) aged approximately 5 to 6 weeks were maintained at 22 ± C and 55% humidity on a 12-hour light/dark cycle and fed Ssniff pellets and tap water ad libitum (ear-tagged). Animals were given subcutaneous daily administrations of the test compounds. NMRI mice (Harlan Winkelmann) were maintained and treated as described for the rats.
General Toxicity Studies
A dose-selection study of 3 months' duration was conducted in mice to determine the optimal dose for long-term carcinogenicity studies (see Table 1 ). In this study, 10 male and 10 female mice were given a daily subcutaneous injection of 0 (vehicle control), 5, 10, and 20 IU/kg of insulin glargine. Three general toxicity studies, of 3, 6, and 12 months' duration, were conducted in rats. The results of the 3-and 6-month studies were used to determine the optimal dose of insulin glargine to be used for long-term carcinogenicity studies. The 12-month study was included for comparison to a previous 12-month study in rats using synthetic [B10-Asp]-insulin before phase III insulin glargine clinical trials in humans were commenced (Jorgensen, Dideriksen, and Drejer 1992) . The numbers of rats and doses of insulin glargine are detailed in Table 1 .
Observations and Measurements
Body weight was measured twice weekly for a period of 3 months in rats or 2 weeks in mice, and once weekly there-after in both species. Survival checks were made, and general health, condition, and behavior were monitored twice daily: eyes (macroscopically; lens and cornea ndings were con rmed with a slit lamp), neurologic condition (corneal re ex, hand grip strength), teeth, and oral mucosa were monitored monthly; and palpation for nodules was carried out once a month for up to 6 months, and twice monthly thereafter.
Laboratory Examinations
Blood samples for hematology were taken prior to sacri ce at the time of necropsy. In addition, when possible, tissue samples were collected from animals that were sacri ced in a moribund state.
Sacri ce and Post Mortem Examinations
Animals that died or were sacri ced were necropsied as soon as possible; the remaining animals were sacri ced on the day of the last dose. Organs were weighed and examined microscopically.
Statistical Analysis
Body weight, hematological examinations, organ weights, and mortality were tested at a level of signi cance of p < .05 using a one-way analysis of variance with sequentially rejective multiple comparisons. Histopathology was tested using a twogroup comparison with the one-sided Fisher's exact test, the Peto mortality-adjusted trend test analysis for neoplastic lesions, and the Cochran-Armitage trend-test analysis for non-neoplastic lesions with respect to dose rates. Only p values of <.05 for rare lesions and p values of <.01 for common lesions were considered to be statistically signi cant. In cases of a signi cant result for the statistical tests against the NaCl control and a signi cant difference between the NaCl control and vehicle control by twogroup comparison, a trend test against the vehicle control was additionally evaluated.
RESULTS
Repeated-Dos e Toxicity Studies
The ndings of the dose selection studies in mice and rats are summarized in Table 1. In the 3-month study in mice, no insulin-related pathologic changes were observed. Decreased granulation of¯-cells in the Langerhans islets of the pancreas were observed in the intermediate-and high-dose groups. The deaths that occurred were related to the exaggerated pharmacodynamic effect of the high dose of insulin (20 IU/kg). Based on these data and for comparison with the results of the rat studies, a dose of 12.5 IU/kg was used in the long-term carcinogenicity study in mice and rats. The lowest dose used in the carcinogenicity study was approximately two times higher than the maximal therapeutic dose used in humans (0.5-1.0 IU/kg). NPH insulin was used for comparison at a dose level of 12.5 IU/kg body weight, resembling the highest dose of insulin glargine. In the 3-month repeat-dose toxicity study, the high dose (40 IU/kg) of insulin glargine caused severe hypoglycemia, resulting in the death of 19 of the 30 animals in this group. Histopathologic examination of these dead animals revealed lique cation of the neocortex with delayed type neuronal cell death, a typical morphologic equivalent of prolonged hypoglycemia. The no-observable-adverse-effec t level (NOAEL), calculated for the purpose of conducting phase III clinical trials in humans, was determined at 4 IU/kg.
In a 6-month study in rats, most of the rats that died had neuronal necrosis within the hippocampus, or cerebrocortical laminated spongiform vacuolation with neuronal necrosis of varying degrees, or both. All insulin glargine-treated rats had dose-dependent pancreatic¯-cell degranulation, which was reversible in most groups after a 4-week recovery period at the end of the study. The NOAEL value for this study was calculated to be 6.3 IU/kg.
The 12-month study in rats was conducted for comparison to a previous 12-month study with synthetic [B10-Asp]-insulin, and to provide information for conducting phase III clinical trials in humans. The dose of insulin glargine was reduced from 40 IU/kg/day (the dose at which toxic effects were expected to occur) to 20 IU/kg/day at day 112 because of a high mortality rate (7 and 8 out of 30 males and females, respectively). Even at the reduced dose of 20 IU/kg, 13 more males and 6 more females died. After histologic examination, the mortality was considered to be due to hypoglycemia and subsequent cardiovascular failure. Based on the data from these pilot studies in rats, a dose of 12.5 IU/kg was considered the maximum tolerated dose (MTD) for a lifetime study.
Long-Term Carcinogenicity Study in Mice
Based on the results of the 3-month dose-nding study, groups of 50 male and 50 female mice were subjected to oncedaily subcutaneous injections with isotonic NaCl (control), the vehicle, 2, 5, or 12.5 IU/kg insulin glargine, or, for comparison, 12.5 IU/kg NPH insulin. Doses of 12.5 IU/kg insulin glargine and NPH insulin are considered to be equivalent. The mortality rate over the 2 years of the study was comparable between treatment groups (Table 2) . After 78 weeks, the mortality rate was in the range of 14% to 40% in males and 28% to 46% in females. The highest mortality was observed in females in the group receiving the low dose of insulin glargine. At study termination at week 107, overall spontaneous mortality was very high in female mice, ranging from 78% to 94%. The corresponding mortality rate in males was 54% to 68%. In both sexes, the highest mortality rate was observed in NaCl controls. Mortality rates were identical in the 12.5 IU/kg insulin glargine and 12.5 IU/kg NPH insulin groups.
During the study, injection site reactions included scabbing, induration, swelling, nodelike changes, solid deposits, thrombosis, and open wounds. These changes occurred with comparable incidence in the vehicle and insulin glargine groups (data not shown). Palpable masses were observed with a similar incidence between groups, except for the higher incidence of palpable masses in males in the low-dose insulin glargine group.
The incidence of tumors of particular interest in this study is detailed in Tables 3A and 3B . There was no difference in the incidence of mammary tumors when comparing the insulin glargine groups with the control groups and the NPH insulin group. Malignant brous histiocytoma (MFH) at the injection sites in male mice were found with a similar incidence in the vehiclecontrol and insulin glargine groups. Compared with the NaCl control, only the low-dose group showed a statistically significant increase in incidence. The distribution of MFH was not dose-dependent. No statistically signi cant increase in subcutaneous MFH was found in insulin glargine-treated female mice when compared with the NaCl control group. Hepatocellular tumors were observed in all groups of male mice, with a significantly increased incidence of hepatocellular adenomas in the vehicle-control, low-, and intermediate-insulin glargine groups; however, the distribution was not dose-related. Other parameters such as food consumption, physical characteristics, and organ weights were similar in all study groups and did not indicate treatment-related effects.
Long-Term Carcinogenicity Study in Rats
Based on the 3-, 6-, and 12-month studies in rats, groups of 50 male and 50 female rats were subjected to once-daily subcutaneous injections with isotonic NaCl (control), the vehicle control, 2, 5, or 12.5 IU/kg insulin glargine, or, for comparison, 5 IU/kg of NPH insulin. Doses of 5 IU/kg insulin glargine and NPH insulin are considered to be equivalent. Rats were given a lower dose of NPH insulin than mice because previous studies have shown that they are more sensitive to the effects of this insulin.
In males, statistical evaluation of the overall study mortality revealed signi cantly increased mortality in vehicle-, insulin glargine-, and NPH insulin-treated groups, compared with the NaCl control (Table 4 ; p < .05). In females, mortality increased dose-dependently in the insulin glargine groups, but was only statistically signi cantly different from the NaCl control for the insulin glargine 12.5 IU/kg and NPH insulin 5 IU/kg dose groups (Table 4 ; p < .05). Comparing the mortality rates in the 5 IU/kg insulin glargine and the 5 IU/kg NPH insulin groups, mortality was generally higher in the NPH insulin group in males (88% vs. 90%) and females (68% vs. 82%). Changes at the injection site, including scabbing, induration, and swollen deposits were noted mainly in the rst year of the study in the control-, vehicle-, and compound-treated animals (data not shown). There was a non-dose-dependent increase in these ndings in the male vehicle and insulin glargine groups, and a marginal increase in the NPH insulin group. The incidence of these changes decreased after week 60, and was not observed after week 90. The incidence of tumors is represented in Tables 5A and 5B . There was no difference in the incidence of mammary tumors when comparing the insulin glargine groups with the control groups and the NPH insulin group. The incidence of subcutaneous MFH found at the injection site was increased in males in the vehicle and all insulin glargine dose groups. MFH occurred at a much lower incidence in female rats in the vehicle and lowand median-dose insulin glargine groups. A slightly higher incidence of pancreatic islet cell adenomas in female rats in the insulin glargine high-dose group compared with the NaCl control was considered to be a random and non-treatment-related event. In male animals, a high incidence of pancreatic islet cell adenomas was observed in the NaCl and NPH insulin groups. Because the incidence in the insulin glargine groups was consistently lower and none was detected in the high-dose insulin glargine group, the occurrence was not considered to be related to insulin glargine administration. Compared with the NaCl control, malignant lymphomas were observed with a statistically increased incidence in male rats in the vehicle-control group but not in the insulin glargine groups and, thus, were considered to be unrelated to insulin glargine treatment. Neuronal necrosis of the cerebrum was present in rats that died or were sacri ced intercurrently in the intermediate-and high-dose insulin glargine and NPH insulin groups. The lesion was attributed to persistent repeated severe episodes of hypoglycemia induced by high doses of insulin. The affected areas are typically susceptible to hypoglycemic damage. Other parameters such as body weight, food consumption, physical characteristics, palpable masses, and organ weights were not affected by treatment.
DISCUSSION
Studies assessing the carcinogenic potential of insulins have not previously been required by registration authorities, and this report is the rst of its kind to present extensive data on the carcinogenic potential of an insulin analogue in rodents.
The present study has comprehensively demonstrated that insulin glargine did not cause mammary tumors in rodents, unlike the insulin analogue [B10-Asp]-insulin. No other neoplastic changes that may affect humans were detected.
This study revealed neoplastic changes that were not related to treatment. In particular, hepatocellular adenomas and carcinomas were observed in mice. The relevance of performing carcinogenicity studies in mice has been questioned because some tumors commonly found with high incidence in mice, in particular liver and lung tumours, are considered to be of doubtful relevance in humans (Monro 1993) . Analysis of regulatory decisions indicates that the rat is the preferred species for long-term carcinogenicity studies (Van Oosterhout et al. 1997) .
The present study revealed an increased incidence in MFH at the injection site, which was associated with the permanent irritation of local connective tissue due to the acidic pH of the vehicle solution. MFH is a recognized tumour in the subcutaneous tissues of laboratory rats and mice, with a higher incidence in males (Greaves and Faccini 1981; Zwicker et al. 1992; Haseman, Bourbina, and Eustis 1994) . Rodents have been shown to develop MFH at the sites of implantation of inert foreign materials and the sites of injection of a number of otherwise innocuous chemicals (e.g., glucose, fructose) (Berenblum 1974; Grasso and Golberg 1967) . In addition, male mice have been shown to develop mesenchymal tumors at the site of injection of 0.25 N HCl buffered to pH 5.0 (Suntzeff, Babcock, and Loeb 1940) . In a review of the induction of subcutaneous soft tissue sarcomas in toxicity studies, Greaves (1990) described how agents not generally considered carcinogenic may give rise to sarcomas around the injection site. Sequential studies of local tissue reactions to repeated subcutaneous injections of noncarcinogenic substances have tended to show a correlation between the nature of the early lesions and the ultimate formation of sarcomas. It appeared that if injected substances failed to elicit a macrophage response, caused little or no damage, and were absorbed from the injection site, neoplasia did not result. In contrast, agents that elicited a response characterized by severe in ammation, tissue damage, a macrophage response, broblastic proliferation, and broplasia tended to be associated with the development of sarcomas. The results of the present study, together with evidence from the literature, indicate that the incidence of MFH is a rodent-speci c event and probably attributable to chronic tissue irritation and in ammation due to the effect of the vehicle on local connective tissues.
MFH in humans are rare, and there is no evidence of an increased incidence of MFH in patients with diabetes. These patients have been receiving insulin delivered in an acid vehicle and with a comparable composition as described for insulin glargine for several decades (The United States Pharmacopeia 1995), and no human cases of internal or local malignancy associated with insulin treatment could be identi ed in the available literature. Therefore, we conclude that the administration of insulin glargine in the acidic vehicle does not represent a cancer risk in humans.
The mortality rates in mice were high, particularly in the last 6 months of the study. However, after 18 months (78 weeks), the mortality in female mice was 28% to 46%, with the highest mortality rate observed in the group receiving the low dose of insulin glargine (2 IU/kg) and the mortality rate in male mice was even lower. International guidelines on carcinogenicity testing generally recommend that mouse carcinogenicity studies should be performed for a minimum of 18 months and a maximum of 24 months. The present study was extended beyond 18 months in mice because the mortality in the NaCl control (34%) and lowdose (2 IU/kg) insulin glargine group (46%) was considered to be too low for lifetime exposure in a carcinogenicity study. The termination of a carcinogenicity study, according to US Food and Drug Administration regulatory guidelines, is acceptable when the numbers of survivors in the low-dose or control group is reduced to 20 to 25 animals. As expected, the mortality rate increased in the last 6 months of the study. The number of survivors in the female control and low-dose groups was reduced to 6% and 10%, respectively.
In mice, the treatment with insulin glargine or NPH insulin did not affect survival compared with the NaCl or vehicle control. In rats, the mortality rate was higher in the vehicle control, the insulin glargine, and NPH insulin groups in males, and in the 12.5 IU/kg insulin glargine and 5 IU/kg NPH insulin groups in females.
Comparing the corresponding 5 IU/kg and 12.5 IU/kg insulin glargine and NPH insulin groups in rats and mice, respectively, mortality rates in rats were lower (rats) or identical (mice) in the insulin glargine group compared with NPH insulin. These results indicate that insulin glargine has no greater toxicity than NPH insulin. However, in rats in the 12.5 IU/kg insulin glargine group, mortality was higher and animals died earlier, than in the NaCl controls. This high mortality is considered to be due to treatment-related hypoglycaemia and subsequent neuronal necrosis or cardiovascular failure. The latter condition is not associated with any speci c morphological changes.
The exaggerated pharmacodynamic effect of hypoglycemia due to high doses of exogenous insulin was expected to contribute to the mortality rate in this study. Further evidence to support this view included the increased incidence of pancre-atic¯-cell degranulation, which indicates a reduced number of insulin-containing storage granules. Such a nding is the morphologic correlate of the chronic inhibition of endogenous insulin synthesis. Exogenous insulin exposure replaces and substitutes endogenous insulin in an experimental setting such as a toxicity study. Chronic exogenous insulin exposure has been demonstrated to induce pancreatic¯-cell degranulation, and is more pronounced the longer the duration of exogenous insulin exposure (Logothetopoulos 1966) .
We conclude from the results of the present study that in rodents, insulin glargine use does not present a carcinogenic risk. Together with the in vitro studies that demonstrate equivalence between human insulin and insulin glargine with respect to IGF-1 receptor binding and mitogenic activity, these results indicate that insulin glargine is unlikely to pose a cancer risk in humans.
